Global Newcastle Disease Vaccine Market is expected to reach USD 462.6 million by 2030

The global Newcastle disease vaccine market size was worth around USD 343.9 Million in 2022 and is expected to reach USD 462.6 Million by 2030, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period.

Newcastle Disease Vaccine is a preventative measure used to control the spread of the highly contagious Newcastle disease in poultry. The disease is caused by a paramyxovirus and affects a wide range of domestic and wild bird species, including chickens, turkeys, pigeons, and ducks. The vaccine is formulated to protect against several strains of the Newcastle disease virus. Newcastle Disease Vaccine is administered to chicks and birds through injection or drinking water, and it is effective in preventing the spread of the disease. The vaccine is developed using different methods, including live attenuated, inactivated, and recombinant vaccines, with each type having its advantages and disadvantages.

The use of the Newcastle Disease Vaccine has become an essential practice in the poultry industry worldwide, helping to prevent economic losses due to the high mortality rates caused by the disease. The vaccine has also been a significant contributor to food security, ensuring that safe and healthy poultry products are available to consumers.

The global Newcastle Disease Vaccine market is driven by factors such as the increasing demand for poultry products, government support for animal health research, and growing awareness among farmers about the benefits of vaccination programs. The market growth is, however, restrained by factors such as the high cost of vaccines, inadequate diagnostic facilities, and the emergence of new strains of the Newcastle disease virus. Nonetheless, opportunities in the market include technological advancements in vaccine production, rising investments in animal health research, and expanding poultry industries in emerging economies. The market players are focusing on developing advanced vaccines, expanding their product portfolios, and collaborating with research institutes and other stakeholders to gain a competitive edge. These factors create ample opportunities for the growth of the market during the forecast period.

The global Newcastle disease vaccine market is segmented based on vaccine type, species, and region.

Based on vaccine type, the market is bifurcated into Live Attenuated, Inactivated, and Thermostable. The live attenuated vaccine segment held the largest market share in 2022 and is further predicted to cite the fastest CAGR during the forecast period. Live Attenuated Vaccines (LAV) have been widely used and preferred over other vaccine types due to their effectiveness, low cost, and ability to provide long-lasting immunity. LAVs have been shown to confer broad-spectrum immunity against different strains of Newcastle disease viruses, making them a popular choice among poultry farmers. These factors will drive the growth of the segment during the forecast period.

Based on species, the market is segmented based on chicken, duck, goose, and others. The chicken segment held the dominating market share in 2022 and is further expected to occupy a significant CAGR during the forecast period. Newcastle Disease Virus (NDV) is a significant threat to the chicken industry, leading to significant economic losses due to high mortality rates and reduced egg production. Therefore, the demand for Newcastle Disease Vaccines is high among chicken farmers, making this segment the most profitable in the market. However, vaccines for other bird species such as ducks and geese are also in demand, especially in regions where these birds are raised commercially or for domestic purposes.

Based on region, the North American region held the dominating market share in 2022 and is further predicted to grow rapidly at a notable CAGR during the forecast period. This is mainly due to the increasing demand for poultry products in the region which has led to a rise in the number of poultry farms, thereby increasing the risk of disease outbreaks. In addition, the growing awareness among farmers about the benefits of vaccination programs and the need for effective measures to control the spread of the disease has driven the regional Newcastle disease vaccine market growth. Furthermore, government initiatives to control the spread of Newcastle Disease have been instrumental in promoting the adoption of vaccines among poultry farmers, thereby boosting the market growth.

This review is based on a report by Zion Market Research, titled “Newcastle Disease Vaccine Market By Vaccine Type (Live Attenuated, Inactivated, Thermostable), By Species (Chicken, Duck, Goose, And Others), and By Region: Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts, 2023 – 2030.”- Report at https://www.zionmarketresearch.com/report/newcastle-disease-vaccine-market

Recent Developments

• In 2021, Elanco Animal Health, an American Pharmaceutical company announced that it had completed the acquisition of Kindred Biosciences, a biopharmaceutical company focused on developing vaccines for pets and livestock. The acquisition included Kindred's Newcastle Disease Virus Vectored vaccine platform, which uses a viral vector to deliver antigens to animals and trigger an immune response. This acquisition will help Elanco to expand its presence in the poultry vaccine market and develop new vaccines for poultry and other animal species.
• In 2020, Merial Animal Health, a multinational animal health company, announced that it had received approval from the European Medicines Agency for a new inactivated vaccine, Vaxxitek® ND-IBD. The vaccine provides protection against both Newcastle Disease and Infectious Bursal Disease in chickens, and its innovative formulation reduces the risk of vaccine reactions.

The global Newcastle disease vaccine market is dominated by players such as:

• Merial
• QYH Biotech
• CEVA
• Yebio
• Ringpu (Tianjin) Bio-Pharmacy Co. Ltd
• Bayer AG
• Hipra,  Anicon Labor GmbH
• Chengdu Tech-bank Biological Products Co. Ltd.
• Ringpu Bio-Technology Co. Ltd.
• MSD Animal Health
• Nisseiken Co.
• Harbin Veterinary Research Institute
• Merck Animal Health
• ChengDu Tecbond
• DHN
• Zoetis
• Elanco (Lohmann)
• CAVAC
• Vaksindo
• FATRO

Global Newcastle disease vaccine market is segmented based on:

By Vaccine Type

• Live Attenuated,
• Inactivated
• Thermostable

By Species

• Chicken
• Duck
• Goose

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com